3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
27
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
4
Sarcoma
2
Urinary Bladder Neoplasms
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Metastatic HER2-positive Breast Cancer
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
HR+HER2- Breast Cancer
1
HER2-low Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Radiosurgery
23
Radiotherapy
20
Temozolomide
17
Lomustine
9
Bevacizumab
8
Surgical Procedures, Operative
7
Procarbazine
6
Vincristine
5
Nivolumab
5
Memantine
5
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Carboplatin
4
Specimen Handling
3
Sodium Chloride
3
Radiation
3
Methylphenidate
3
Mental Status and Dementia Tests
3
Granulocyte Colony-Stimulating Factor
3
Gefitinib
3
Cyclophosphamide
3
Corticotropin-Releasing Hormone
3
Carmustine
3
icotinib
2
etoposide phosphate
2
efaproxiral
2
X-Rays
2
Tranexamic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Brain Neoplasms
×
eribulin
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled